Business context and reporting period
The filing is Coherus BioSciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2014, filed March 23, 2015. The request metadata names Coherus Oncology, Inc.; the registrant identified in the filing is Coherus BioSciences, Inc. Coherus was a clinical-stage biosimilar developer with no approved products or commercial product sales. Its principal programs were CHS-0214 (etanercept/Enbrel), CHS-1420 (adalimumab/Humira) and CHS-1701 (pegfilgrastim/Neulasta).
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Total revenue | $31.1 million | $2.8 million |
| Operating expenses | $95.8 million | $38.7 million |
| Operating loss | $64.7 million | $36.0 million |
| Net loss | $87.2 million | $53.6 million |
| Net loss per share | $10.64 | $16.10 |
| Cash used in operating activities | $23.9 million | Cash provided: $15.4 million |
| Cash and cash equivalents, year-end | $150.4 million | $39.6 million |
| Working capital | $127.4 million | Deficit: $8.0 million |
2014 revenue was primarily collaboration and license revenue, not product sales. The increase chiefly reflected Baxter-related deferred revenue amortization and a $10.0 million substantive milestone. Baxter accounted for 92% of annual revenue. Gross margin is not presented as a meaningful operating measure for this pre-commercial company; the filing does not provide a clear product gross margin. Operating cash flow turned negative in 2014 despite higher reported revenue, while financing cash flow was $136.0 million, primarily from the Series C financing and IPO. Net investing cash use was $0.5 million; cash increased $110.8 million during the year.
At year-end, total assets were $187.2 million and total liabilities were $120.5 million. Convertible notes were zero following conversion into preferred stock; preferred stock then converted to common stock at the IPO. No conventional debt balance was reported at year-end. Deferred revenue and a $27.7 million contingent liability to collaborator were significant liabilities, not reported as borrowings.
For Q4 2014, reported revenue was $6.5 million, operating expenses were $33.1 million and net loss was $29.0 million. Annual net loss attributable to Coherus was $87.1 million.
Material changes versus the prior comparable period
- Revenue rose substantially from $2.8 million to $31.1 million, largely from collaboration accounting and milestone recognition rather than product sales.
- R&D expense increased to $78.2 million from $31.3 million as CHS-0214 entered Phase 3 and the other programs advanced; G&A rose to $17.6 million from $7.5 million, including higher staffing, stock compensation and public-company costs.
- Net loss widened to $87.2 million from $53.6 million. Other expense increased to $18.6 million, including fair-value charges for preferred-stock warrants and InteKrin contingent consideration.
- Cash and working capital improved significantly following $80.2 million of net IPO proceeds and $54.7 million of net Series C proceeds. The IPO also converted preferred stock and eliminated the reported convertible-note balances.
- The company acquired InteKrin in February 2014 for approximately $5.0 million of consideration, including contingent consideration, adding the INT-131 program and a Russian subsidiary.
Outlook, commentary, risks and unusual items
- Management expected available cash plus anticipated Daiichi Sankyo and Baxter funding to cover planned operations for at least 12 months from the filing, but said additional capital would be needed to obtain approvals and commercialize products. Funding availability and terms were not assured.
- CHS-0214 was in two Phase 3 trials; management targeted European and Japanese filings in 2016, subject to positive results and regulatory requirements. The trials paused after particles were found in four syringes from one lot in October 2014; investigation attributed them most likely to a non-recurring equipment anomaly, and dosing resumed in December. Enrollment targets increased because of the pause.
- CHS-1420 completed Phase 1 and management planned a Phase 3 psoriasis trial in the first half of 2015, with U.S. filing targeted for 2016 and E.U. filing for 2017.
- For CHS-1701, the company shifted from the 351(a) novel-biologic route to the 351(k) biosimilar route, targeting a U.S. filing in Q4 2015 or Q1 2016. Its earlier Phase 1 study did not establish the pharmacokinetic bioequivalence needed for the 351(k) pathway; a new pivotal PK/PD study and an immunogenicity study were planned. FDA written feedback and initiation of the new study occurred in March 2015, after year-end.
- Major risks include clinical or regulatory failure, evolving biosimilar requirements, patent disputes and delayed market entry, competition from larger developers, reliance on single-source contract manufacturers and CROs, reimbursement and pricing pressure, and continued cash burn. U.S. commercialization of CHS-0214 faces originator patents Coherus said could extend to 2028–2029.
- The company reported no material litigation. It disclosed a previously identified material weakness related to complex securities valuation and stated remediation steps had been taken; no material weakness was identified in the 2014 audit. The auditor issued an unqualified opinion on the financial statements but did not audit internal control effectiveness.
Important facts for investors to verify
- Whether reported collaboration revenue, milestone receipts and deferred revenue translate into recurring funding, and how much additional capital will be required.
- Clinical enrollment, results, timelines and regulatory feedback for all three lead programs, especially the new CHS-1701 biosimilarity study.
- Whether the CHS-0214 particulate investigation is fully resolved and whether any further manufacturing or trial-supply disruption occurs.
- Patent scope, litigation exposure and realistic launch timing in each target market, including the stated U.S. etanercept patent barriers.
- Partner commitments and economics, including Baxter’s potential claw-back, milestone conditions, and reliance on Daiichi Sankyo and Baxter outside the United States.
- Cash burn, contingent obligations and liquidity runway; management’s 12-month funding expectation depends on assumptions and anticipated partner funding.